Cargando…

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

SIMPLE SUMMARY: Nivolumab combined with ipilimumab has improved the prognosis of patients with advanced melanoma. However, this therapy is frequently associated with immune-related adverse events. Published data suggested that objective responses rates appear to be superior in patients who developed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serna-Higuita, Lina María, Amaral, Teresa, Forschner, Andrea, Leiter, Ulrike, Flatz, Lukas, Seeber, Olivia, Thomas, Ioannis, Garbe, Claus, Eigentler, Thomas Kurt, Martus, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657404/ https://www.ncbi.nlm.nih.gov/pubmed/34885249 http://dx.doi.org/10.3390/cancers13236141

Ejemplares similares

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
por: Amaral, Teresa, et al.
Publicado: (2020)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
por: Wagner, Nikolaus B, et al.
Publicado: (2018)

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
por: Weide, Benjamin, et al.
Publicado: (2013)

Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis
por: Weide, Benjamin, et al.
Publicado: (2013)

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases
por: Held, Laura, et al.
Publicado: (2013)

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
por: Meckbach, Diana, et al.
Publicado: (2014)

The need for psycho-oncological support for melanoma patients: Central role of patients’ self-evaluation
por: Mayer, Simone, et al.
Publicado: (2017)

Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study
por: Wiens, Lisa, et al.
Publicado: (2021)

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
por: Forschner, Andrea, et al.
Publicado: (2019)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany
por: KRAMB, Felix, et al.
Publicado: (2022)

Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma
por: Pflugfelder, Annette, et al.
Publicado: (2011)

Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour
por: Weide, Benjamin, et al.
Publicado: (2013)

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
por: Amaral, Teresa, et al.
Publicado: (2020)

Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
por: Elsaeßer, Otmar, et al.
Publicado: (2012)

Development of an Image Analysis-Based Prognosis Score Using Google’s Teachable Machine in Melanoma
por: Forchhammer, Stephan, et al.
Publicado: (2022)

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma
por: Wölffer, Marcus, et al.
Publicado: (2022)

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
por: Garbe, Claus, et al.
Publicado: (2020)

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
por: Wagner, Nikolaus B, et al.
Publicado: (2021)

319 Bronchial Hyperresponsiveness in Obese Adolescents
por: Ramírez, Gabriela, et al.
Publicado: (2012)

Health Tract, No. 319: Poverty and Longevity
Publicado: (1868)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
por: Garbe, Claus, et al.
Publicado: (2011)

Fungal Planet description sheets: 281–319
por: Crous, P.W., et al.
Publicado: (2014)

SAT319 Megestrol-induced Adrenal Insufficiency
por: Alcorn, Chris, et al.
Publicado: (2023)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018)

(103)Pd versus (125)I ophthalmic plaque brachytherapy: preoperative comparative radiation dosimetry for 319 uveal melanomas
por: Finger, Paul T., et al.
Publicado: (2014)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

MiR319 mediated salt tolerance by ethylene
por: Liu, Yanrong, et al.
Publicado: (2019)

Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
por: Wessely, Anja, et al.
Publicado: (2020)

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
por: Garbe, Claus, et al.
Publicado: (2022)

Determinants of survival in patients with brain metastases from cutaneous melanoma
por: Staudt, M, et al.
Publicado: (2010)

What difference does multiple imputation make in longitudinal modeling of EQ-5D-5L data? Empirical analyses of simulated and observed missing data patterns
por: Rösel, Inka, et al.
Publicado: (2021)

Imaging characteristics of cardiac metastases in patients with malignant melanoma
por: Zitzelsberger, Tanja, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b4jsvces9olquqmusf7bbt3do9